Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

Pediatrics

Volumn 104, Issue 3 I, 1999, Pages 419-427

  Joffe, Steven ^a   Ray, G Thomas ^b   Escobar, Gabriel J ^b,c   Black, Steven B ^b,c   Lieu, Tracy A ^b,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DIVISION OF RESEARCH   (United States)

^c KAISER PERMANENTE   (United States)

^d HARVARD PILGRIM HEALTH CARE   (United States)

Author keywords

Bronchiolitis; Bronchopulmonary dysplasia; Chronic lung disease; Cost effectiveness analysis; Infections; Intensive care; Neonatal; Neonatal infections; Passive immunization; Prematurity; Prophylaxis; Respiratory; Respiratory syncytial virus infections; Seasonal variation

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN INTENSIVE CARE; PASSIVE IMMUNIZATION; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEASONAL VARIATION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS;

EID: 0032881631     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.104.3.419     Document Type: Article

References (25)

1. Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illness in the first year of life. Am J Epidemiol. 1991;133:1135-1151
2. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988; 82:199-203
3. Groothuis JR, Simoes EAF, Hemming VG, et al. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics. 1995;95:463-467
4. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics. 1991; 88:527-532
5. Law BJ, De Carvalho V, and the Pediatric Investigators Collaborative Network on Infections in Canada. Respiratory syncytial virus infections in hospitalized Canadian children: regional differences in patient popillations and management practices. Pediatr Infect Dis J. 1993;12:659-663
6. Meert K, Heidemann S, Lieh-Lai M, et al. Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host. Pediatr Pulmonol. 1989;7:167-170
7. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr.1992;121:348-354
8. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99
9. Wang EEL, Law BJ, Stephens D, et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126: 212-219
10. Wang EEL, Law BJ, Robinson JL, et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics. 1997;99(3). URL: http://www.pediatrics.org/cgi/content/ full/99/3/e9
11. Nachman S, Navaie-Waliser M, Qureshi M. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow-up. Pediatrics. 1997;100(6). URL: http://www. pediatrics.org/cgi/content/full/100/6/e8
12. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102:531-537
13. Joffe S, Escobar GJ, Armstrong MA, Black SB, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. In press
14. Committee on Infectious Diseases and Committee on Fetus and Newbom. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics. 1998;102:1211-1216
15. Storch GA. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics. 1998;102:648-650
16. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Managed Care. 1996;2: 851-861
17. O'Shea TM, Sevick MA, Givner LB. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants. Pediatr Infect Dis J. 1998;177:587-593
18. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med. 1998;152:358-366
19. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:176-213
20. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:176-213
21. Bindley-Western Wholesale Catalogue. Indianapolis, IN: November 5, 1998
22. US Bureau of Labor Statistics. Bulletin 2445. Employment and Earnings. March and June issues. http://www.census.gov/prod/1/gen/ 95statab/labor.pdf
23. Kranczer S. Mixed life expectancy changes. Stat Bull. 1996;77:29-36
24. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 1996
25. O'Brodovich HM, Mellins RB. Bronchopulmonary dysplasia. Am Rev Respir Dis. 1985;132:694-709